Biography

In pursuit of an academic life, after receiving my MD from Tehran University of Medical Sciences, I moved to Beautiful British Columbia to start my PhD at UBC, with a focus on lipid metabolism, atherosclerosis, inflammation, and vascular bioplay. Alongside research, I was involved with Medical and Dental undergraduate teaching in areas such as principals of human biology, problem-based learning, Doctor, patient, and society (DPAS), and clinical skills. During my PhD, I also learned that pathology is the most fulfilling area of Medicine for me and started my postgraduate medical training at the University of British Columbia in Anatomical Pathology. The complexity of diagnostic Renal Pathology, utilization of multiple modalities to study a small fragment of tissue from different perspectives, requirement for a solid understanding of clinical aspects, and close interaction with the nephrologists drew me to Renal Pathology. I completed my renal pathology fellowship at University of Washington, Seattle in 2018 after which I moved back home to join the pathology department at St. Paul's Hospital.

Academic Background

• MD, Tehran University of Medical Sciences

• PhD, University of British Columbia

• Anatomic Pathology Residency, University of British Columbia

• Renal Pathology Fellowship, University of Washington

Expertise / Research Interests / Teaching Interests

• Renal Pathology

• Renal allograft pathology

• Vascular biology

• Personalized medicine, predictive and prognostic biomarkers

Publications

• Ouro A, Arana L, Riazy M, Zhang P, Gomez-Larrauri A, Steinbrecher UP, Duronio V, Gomez-Muñoz A. “Vascular endothelial growth factor mediates ceramide 1-phosphatestimulated macrophage proliferation” Exp Cell Res. 2017;361(2):277-283.

• Kalloger SE*, Riazy M*, Tessier‐Cloutier B, Karasinska JM, Gao D, Peixoto RD, Samimi S, Chow C, Wong H, Mackey JR, Renouf DJ, Schaeffer DF. “A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine” J Pathol Clin Res. 2017; 3(3): 179–190. (*: equal contribution)

• Riazy M, Kalloger SE, Sheffield BS, Renata D. Peixoto RD, Li-Chang HH, Scudamore CH, Renouf DJ, Schaeffer DF. “Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma” Mod Pathol. 2015;28(10):1383-9.

• Zhang P, Riazy M, Gold M, Tsai SH, McNagny K, Proud C, Duronio V. “Impairing eukaryotic elongation factor 2 kinase activity decreases atherosclerotic plaque formation” Can J Cardiol. 2014;30(12):1684-8.

• Lam MCW, Singham J, Hegele RA, Riazy M, Hiob MA, Francis G, Steinbrecher UP. “Familial hypobetalipoproteinemia-induced nonalcoholic steatohepatitis” Case Rep Gastroenterol. 2012;6(2):429-37.

• Riazy M, Lougheed M, Adomat HH, Guns ES, Eigendorf GK, Duronio V, Steinbrecher UP. “Fluorescent adducts formed by reaction of oxidized unsaturated fatty acids with amines induce macrophage growth” Free Radic Biol Med. 2011;51(10):1926-1936.

• Riazy M, Chen JC, Yamamato Y, Yamamato H, Duronio V, Steinbrecher UP. “OxLDL mediated survival of macrophages does not require LDL internalization or signalling by major pattern recognition receptors” Biochem Cell Biol. 2011;89(4):387-95.

• Chen JH, Riazy M, Wang SW, Dai JM, Duronio V, Steinbrecher UP. “Sphingosine kinase regulates oxidized low density lipoprotein-mediated calcium oscillations and macrophage survival” J Lipid Res. 2010;51(5):991-8.

• Schaeffer DF*, Riazy M*, Parhar KS, Chen JH, Duronio V, Sawamura T, Steinbrecher UP. “LOX-1 augments oxLDL uptake by lysophosphatidylcholine-stimulated murine macrophages but is not required for oxLDL clearance from plasma” J Lipid Res. 2009;50(8):1676-84. (*: equal contribution)

• Chen JH, Riazy M, Smith EM, Proud CG, Steinbrecher UP, Duronio V. “Oxidized LDL mediated marophage survival involves Elongation Factor-2 Kinase” Arterioscler Thromb Vasc Biol. 2009;29(1):92-8.

• Riazy M, Chen JH, Steinbrecher UP. “VEGF secretion by macrophages is stimulated by lipid and protein components of OxLDL via PI3-kinase and PKCζ activation and is independent of OxLDL uptake” Atherosclerosis. 2009;204(1):47-54.